Anchorage of cells to the extracellular matrix and integrinmediated signals play crucial roles in cell survival. We have previously shown that during growth factor deprivationinduced apoptosis in human umbilical vein endothelial cells (HUVECs), key molecules in focal adhesions and adherens junctions are cleaved by caspases. In this study we provide evidence for a selective upregulation of cell-associated matrix metalloproteinases (MMPs). We observe a physical association of MMP2 with b1 and av integrins, which increased threeto fourfold during apoptosis and is dependent upon integrin b1 levels and activation state. Both enforced activation of b1 integrin by a specific antibody and inhibition of MMPs protect HUVECs from apoptosis. We hypothesize that, prior to the commitment to apoptosis,`inside-out' signals initiated by the apoptotic stimulus alter cell shape together with the activation states and/or the availability of integrins, which promote matrix-degrading activity around dying cells. This`auxiliary' apoptotic pathway may interrupt ECM-mediated survival signaling, and thus accelerate the efficient execution of the cell death program.
Introduction
Human umbilical vein endothelial cells (HUVECs) undergo apoptosis when deprived of growth factors (GFs). Endothelial cells in organs preserved in low or no serum conditions for transplant appear particularly vulnerable to apoptosis, 1,2 and vascular endothelial growth factor (VEGF) deprivationinduced apoptosis is a component of capillary regression in vivo. 3, 4 Among the first morphologic changes after induction of apoptosis by removal of GFs are loss of focal adhesions and retraction from the extracellular matrix (ECM). 5 During this process, key molecules in focal adhesions and in adherens junctions are cleaved by caspases. 5, 6 We have previously suggested that specific signaling 7 and architectural components 5, 6 are modified during the disassembly of cell ± matrix and cell ± cell contacts in the apoptotically dying cell, thus contributing to and propagating the apoptotic process by actively interrupting survival signals from the ECM and neighboring cells.
The ECM plays a critical role in determining the fate of a cell. 8 Anchorage of cells to the ECM has been implicated in their survival, 9 since its prevention induces apoptosis in endothelial and epithelial cells in vitro and in vivo. 9 ± 12 Integrins are the architectural and signaling mediators that link the ECM with the focal adhesion complex. This complex acts as an integrative module for incoming signals, and orchestrates the intricate interrelationship between the ECM, the cytoskeleton, and signaling cascades. 13 ± 16 Interference with integrin-mediated survival signals, either by depriving cells of ECM 10, 11 or destroying their ECM environment by misexpression of matrix metalloproteinases (MMPs), leads to apoptosis. 17 Inversely, inhibition of MMPs during the involution of the mammary gland after lactation, prevents the scheduled apoptosis of alveolar epithelium and delays mammary involution. 12, 18 Therefore it appears that epithelial and endothelial cell survival is dependent on signals from integrins and the regulated proteolysis of their ECM ligands.
The extremely efficient process of endothelial cell disengagement from the ECM that we observe after induction of apoptosis prompted us to examine whether dying HUVECs activate endogenous mechanisms to actively promote detachment from the ECM and whether this may serve to accelerate apoptosis. In particular, we examined alterations in integrin function and MMP activities and their involvement in the apoptotic process.
enzymes induces apoptosis in vivo and in vitro, presumably by disengaging integrins. 17 Therefore, we tested whether the apoptotic stimulus induces the matrix-degrading enzymes of the dying cell. After 12 h of GF withdrawal, detached, apoptotic endothelial cells accounted for 40 ± 45% of the total cell population. 7 By gelatin zymography, we observed a distinct upregulation in apoptotic cells of the 65 and 60 kDa forms of MMP2, which corresponded to the intermediate (2.5+0.2-fold increase) and active form (2.3+0.3-fold increase), respectively, compared with controls ( Figure 1A ). Western blots confirmed these results (data not shown), and analysis of the conditioned medium revealed an increase with time in both the pro-enzyme and processed forms of MMP2 during apoptosis ( Figure 1B , neo-conditions, and Figure 2) .
To exclude the possibility that the endogenous activation of MMP2 results from an absence of MMP inhibitors present in the regular growth media, we used HUVECs retrovirally transduced with Bcl-2, which are resistant to GF deprivation-induced apoptosis. 19 These cells showed no major MMP2 activation after GF deprivation, whereas the transduced control cells exhibited a time-dependent activation of MMP2, associated with the cell and in the conditioned media ( Figure 1B) .
Plasminogen activation has been associated with the degrative phase in macrophage apoptosis. 20 Therefore, we examined whether other proteolytic enzymes involved in ECM degradation are induced during apoptosis and found that MMPs were differentially regulated during apoptosis: whereas MMP3 and MMP9 were not detected by zymography in cells, and the low levels of the latter in the conditioned media did not change (data not shown), the expression of MMP1 was increased in apoptotic cells compared with control cells ( Figure 1A) . A different type of matrix-degrading enzyme, urokinase-type plasminogen activator (uPA), also increased after GF deprivation, as seen on casein/plasminogen zymograms ( Figure 1A ): uPA was low in control cells and significantly induced in apoptotic cells. Again, Bcl-2 overexpression in HUVEC that protects them from GF-induced apoptosis reduced the increase in uPA after GF withdrawal (data not shown).
Metalloproteinase-mediated activation of MMP2 and inhibition of MMP activity are protective
The MMP inhibitor BB-94, but not the 1000-fold less effective BB-374, potently prevented the activation of MMP2, both in cells and in the conditioned media, during apoptosis, whereas it had no effect on the upregulation of uPA ( Figure 2 and data not shown). This observation suggested an MMP-dependent process of MMP2 activation during apoptosis. Therefore, we tested whether enzymes of the family of membrane-type matrix metalloproteinases (MT ± MMPs) known to activate MMP2 21 play a role in our system. We evaluated levels of MT1-MMP known to be involved in MMP2 activation by Western blot analysis ( Figure 3A) . In apoptotic cells, native MT1 ± MMP is processed to a 40 ± 44 kDa fragment consistent with autoprocessing of MT1 ± MMP. 22 Although MT ± MMP activity cannot be measured directly, we made use of its differential susceptibility to inhibition by tissue inhibitors of metalloproteinases (TIMPs): low levels of TIMP2 are required for MT1 ± MMP-mediated MMP2 activation, but high levels of only TIMP2, and not TIMP1, can inhibit activation of MMP2 by MT1 ± MMP. 17, 23 In our system, addition of recombinant TIMP2 was as effective as BB-94 in preventing the appearance of the were performed on cell lysates from the same cell populations as described and are representative of two and three replicate experiments, respectively. (B) HUVECs overexpressing either Bcl-2 or the neomycin resistance gene alone were deprived of GFs for the indicated times, and 10 mg of cell lysates of pooled cell populations and the corresponding conditioned media (1% v/v) were subjected to gelatin zymography. The data are representative of three replicate experiments Figure 2 The metalloproteinase inhibitor BB-94 inhibits the activation of MMP2 but not the increase of uPA during apoptosis. Gelatin zymography (n=4) was performed on HUVEC lysates and conditioned media after GF deprivation in the presence or absence of 16 mM BB-94 for the indicated times. Conditioned media from the same experiment were subjected to casein/ plasminogen zymography (n=3). The major casein-degrading activity of approximately 80 ± 85 kDa, corresponding to a uPA/PAI-1 complex, is shown in the third panel 65 kDa and 60 kDa forms of MMP2 during apoptosis, whereas TIMP1 had no effect ( Figure 3B ). This result implies that MT ± MMPs are involved in MMP2 activation.
Caspases could also potentially contribute to the activation of MMP2. This possibility was examined with the potent inhibitor of caspases ZVAD-fmk. ZVAD-fmk inhibited the generation of the active 60 kDa form of MMP2 in a dose-dependent manner, which was accompanied by a concurrent accumulation of the intermediate 65 kDa form ( Figure 3B ). Thus, the processing of the intermediate to active MMP2 form appears to depend on both caspases and MT ± MMPs. Although a plasmindependent mechanism of MMP2 activation has also been described, 24 aprotinin had no effect on MMP2 activation (data not shown).
To test whether the endogenous activation of MMPs may contribute to apoptosis, we added the MMP inhibitor BB-94. Addition of BB-94 substantially decreased apoptosis with an 89% suppression of cell death 4 h after GF deprivation, 40 ± 45% suppression during the following 8 h, and 24% at 24 h ( Figure 3C ). Thus, inhibition of MMPs was effective primarily at early stages following GF-deprivation. The role of MMP2 activation in apoptosis was further investigated by the examination of DNA fragmentation by FACS 1 analysis 5 h after GF deprivation in the presence and absence of TIMP2 ( Figure 3C ). In the absence of TIMP2, 33% of the cells had significant DNA fragmentation, whereas only 19% were detected in the presence of TIMP2 ( Figure 3D ). Thus, both the broad-based MMP inhibitor BB-94 and TIMP2 significantly delay apoptosis in GF-deprived endothelial cells.
During apoptosis the cellular localization of MT1 ± MMP and MMP2 is altered, and MMP2 is recruited to b1 and av integrins As MMP2 can bind to the avb3 integrin and colocalize with integrins at focal adhesion sites, 25, 26 we hypothesized that recruitment of MMP2 to integrins after an apoptotic stimulus may promote disengagement from the matrix. We compared the cellular localization of MT1 ± MMP and MMP2 with phosphopaxillin, a component of focal adhesions, by confocal microscopy in control cells and viable cells still adherent 1.5 h after GF deprivation ( Figure 4A ,B). Although these GFdeprived cells are still viable (not committed to apoptosis because re-addition of GFs rescues all cells), localization of staining for both MT1 ± MMP and MMP2 shifted to focal adhesion sites with GF deprivation. This contrasts with control cells in complete media with GFs in which MMP2 and MT1 ± MMP were localized intracellularly and not associated with focal adhesion sites ( Figure 4A,B) .
To test whether MMPs physically associate with integrins, we immunoprecipitated av and b1 integrins from control, viable (GF deprived but not committed to apoptosis), and apoptotic cells and tested the immunoprecipitates for enzymatic activity on gelatin zymograms. In av immunoprecipitates, the main gelatinolytic activity is attributed to MMP2, which we confirmed by immunoblotting ( Figure 4C ). We observed more MMP2 in av immunoprecipitates from apoptotic cells (3.2+0.4-fold over control, n=3) and viable cells (2.1+0.2-fold higher than control, n=3). In b1 immunoprecipitates, there was no MMP2 activity in zymograms (data not shown). However, after SDS-treatment and reduction of the samples, we detected MMP2 associated with b1 on Western blots ( Figure 4C ), which was increased in viable cells (3.13+0.3-fold above controls, n=3) and further upregulated in apoptotic cells (4.22+0.5-fold above controls, n=3). Therefore, it appears that MMP2 is actively recruited to av and b1 integrins during apoptosis. In the case of b1, this occurs in spite of decreased levels and altered processing of the b1 integrin ( Figure 4C ).
Integrin b1 levels and activation state are decreased during apoptosis, and enforced activation of integrin b1 is protective and suppresses recruitment of MMP2 to b1 integrin Cell surface expression of integrin b1 and activated b1 were evaluated in control and apoptotic cells ( Figure 5A ). We detected a 65% reduction in the total cell surface levels of b1 and activated b1 (with a conformation-specific antibody) in apoptotic cells, compared with controls after 16 h ( Figure 5A ). To test whether the reduction in activated b1 may contribute to apoptosis, we added a b1-activating antibody, 8A2 27,28 with GF deprivation. 8A2 substantially inhibited apoptosis up to 32 h after GF deprivation ( Figure 5B ). In a replicate experiment, the percentage of apoptotic cells after 10 h with b1-activating antibody was 45+4%, whereas the percentage of apoptotic cells was 67+6% after 10 h with a non-blocking antibody to av integrin. (n=3). HUVECs were deprived of GFs in the presence or absence of 10 mg/ml b1-activating antibody 8A2 for the indicated times, and detached apoptotic cells were expressed as per cent of total cell number. Each column represents mean+SD (n=3), with *P=0.0018 and +P50.0008 considered very significant and extremely significant, respectively (student t-test used). (C) HUVECs were deprived of GFs in the presence or absence of 10 mg/ml of the b1-activating antibody 8A2 for 12 h, and the level of MMP2 in total cell lysates (pooled apoptotic and viable) and in immunoprecipitates with anti-b1 antibody was evaluated by zymography and Western analysis, respectively
To determine whether the association of MMP2 with b1 is regulated by the b1 activation state, we added the b1-activating antibody 8A2 during GF withdrawal. After 12 h of GF deprivation, less active MMP2 was observed in cells treated with 8A2 (69+6% of untreated control; Figure 5C ), and decreased levels of MMP2 were found in b1 immunoprecipitates from 8A2-treated cells (73+8% of untreated controls; Figure 5C ). Thus, recruitment of MMP2 to the b1 integrin appears to be inversely correlated with the b1 integrin activation state.
Discussion Possible mechanisms of MMP activation and recruitment to integrins during endothelial apoptosis
Our studies demonstrate a selective regulation of ECMdegrading enzymes during HUVEC apoptosis: expression of MMP1 and uPA is increased, MMP2 is activated, active MT1 ± MMP decreases with a loss of the pro-form, and MMP3 and MMP9 are unaffected. The ability of TIMP2, but not TIMP1, to inhibit the activation of MMP2 in our system implicates MT ± MMPs in the activation of MMP2 during apoptosis, without excluding the possibility of autoactivation via a proximity mechanism. 29 We observe that ZVAD-fmk prevents the generation of the active, but not the intermediate, MMP2 form, with an accumulation of the latter, suggesting that cellular changes preceding the commitment to apoptosis are involved in the generation of the intermediate MMP2 form, whereas the final processing of the intermediate to active MMP2 is dependent on both metalloproteinases and caspases. Such cellular changes may involve both suppression of integrin function and alteration of cytoskeletal architecture, as blockade of the a5b1 integrin in adherent fibroblasts activates MMP1 through Rac1-induced cell rounding and reduction of stress fibers. 30 We have observed a dramatic change in the actin cytoskeleton early after GF deprivation. 7 Actin depolymerization by cytochalasin D, or a decrease of mechanical strain, induces MMP1 and activates MMP2. 26,31 ± 33 Additionally, integrin activation is sufficient to prevent MMP2 activation, even in a rounded cell. 34 We have no evidence for direct activation of MMP2 by caspases. Incubation of recombinant caspases with pro-MMP2 does not result in an increase in gelatinolytic activity of MMP2 (data not shown). However, caspases may participate through indirect mechanisms. The generation of the fully active MMP2 from the intermediate form has been shown to be dependent on the autocatalytic activation in transit by active MMP2 bound to avb3 integrin. 35 The increased association of MMP2 with integrins avb3 and b1 in apoptosing cells may promote this mode of activation. Caspases may participate in the generation of the close spatial proximity required for this mode of activation through conformational changes of the plasma membrane they induce during apoptosis, such as membrane blebbing mediated by cleavage and activation of Rho-activated kinase-I. 36, 37 Our data show a progressive increase in the association of MMP2 with av and b1 integrins in HUVECs during apoptosis. Treatment of cells with the b1-activating antibody 8A2 decreases the association between MMP2 and b1 and inhibits the activation of MMP2. However, our studies do not allow us to distinguish whether integrin activation or enhanced adhesion or both are responsible for the decreased association of MMP2 and the inhibition of MMP2 activation associated with 8A2 treatment.
Disruption of ECM-mediated survival signaling: a putative auxiliary pathway of apoptosis
Endothelial cell shape is highly malleable to instructions provided by the ECM and is crucial for survival, suggesting a cell geometry permissive for or actively contributing to apoptosis. 38 Our study provides evidence for multiple mechanisms of endogenous cell shape regulation during apoptosis and supports a model in which the apoptotic program utilizes modulation of cell shape and interruption of ECM-derived survival signals for its own propagation.
It is conceivable that the downregulation of cell surface integrin expression during apoptosis, as detailed in this study, impairs integrin-mediated survival signaling. Reduced endothelial adhesion from inactivation of avb3 is observed after treatment with tumor necrosis factor a (TNFa) and interferon-g, which induces endothelial apoptosis in the vasculature of melanoma metastases in vivo. 39 Activation of b3 with a specific antibody restores adhesion and survival. Integrin activation with Mn +2 also attenuates endothelial apoptosis induced by combined treatment with TNFa, interferon-g, and melphalan. 39 Our demonstration of a protective effect of enforced b1 activation provides further support for the idea that decreased integrin levels and/or activation mediated through the integrin cytoplasmic domains may accelerate the apoptotic process in endothelial cells.
Although a substantial reduction in integrin levels is seen in the apoptotic cells (Figure 5A ), the total levels of b1, av, and avb3 on the cell surface do not change during the first 4 h of GF deprivation (100+15%, 88+13%, and 96+7.9%, respectively, by FACS 1 analysis). During this period, there is very little apoptosis (7.3+5.6%), and the cells can be rescued by resupplementation of GF. However, dramatic alterations of cell shape occur during this period, including cell retraction, collapse of the actin cytoskeleton, and loss of focal contacts (Figure 4) . 5 These effects are reversible with re-addition of GF, consistent with the observation that disruption of focal adhesions is an early, but not irrevocable, event in endothelial cell apoptosis. 40 Integrin disengagement from the matrix could either be the cause of, or result from, the loss of focal contacts that would lead to an increase in the proportion of free' integrins on the cell surface ( Figure 6 ). However, the persistence of such free, unligated integrins has recently been shown to actively mediate a form of apoptosis termed integrin-mediated death' via the recruitment of caspase-8 to the cytoplasmic domain of the unligated integrin. 41 This process is independent of the loss of adhesion per se (anoikis) and mediates endothelial apoptosis when endothelial cells are plated on an`inappropriate' matrix. 42 Inappropriate matrices may result from the degradation and alteration of the ECM by activated MMPs, as shown for the involution of the mammary gland, where ECM structures required for cell survival are lost through the activity of MMPs. 12 In angiogenesis, increased association between MMPs and avb3 in endothelial cells plays a role in focal degradation of ECM. 25 In our study, recruitment of MMP2 to integrins may serve to alter the matrix microenvironment of the integrin and disengage it from the ECM. Thus, unligated integrins would promote apoptosis by both loss of ECM-mediated survival signaling and active induction of apoptosis by integrin-mediated death ( Figure  6 ). MMP inhibitors, such as BB94 and TIMP2, prevent MMP activation and protect against apoptosis, whereas 8A2 protects via an enforced activation (and engagement) of integrins. The difference between TIMP2 inhibition of apoptosis (43%) and BB-94 inhibition (89%) may reflect the broader inhibitory capabilities of BB-94, which also inhibits another class of metalloproteinases, the ADAMs, such as the TNFa convertase. 43 The activation of uPA in our system may also contribute to apoptosis and thus account for the residual part of the apoptotic process that is unaffected by MMP inhibition (Figure 3) . The notion that the uPA system may be involved in apoptosis is supported by findings that plasminogen activator inhibitor 1 inhibits apoptosis in the promotion of tumor growth. 44 Proteolysis of ECM may itself promote the apoptotic process ( Figure 6 ). A number of endogenous inhibitors of angiogenesis, such as endostatin, arresten, canstatin, and tumstatin, which bind to, or functionally disrupt, integrins, 42 constitute fragments of basement membrane proteins. Several of these molecular fragments, such as tumstatin (the NC1 domain of a3 chain of type IV collagen) or canstatin (a2 chain of type IV collagen), are potent inducers of apoptosis in endothelial cells. 45, 46 The generation of these fragments may be the result of both matrix synthesis/ deposition and proteolysis through matrix-degrading enzymes. Smaller RGD peptides induce apoptosis by direct activation of caspases, 47 and it is conceivable that degraded matrix peptides containing the RGD sequence could contribute to apoptosis.
We previously described dissolution of focal adhesions during endothelial apoptosis and speculated that ECMmediated survival signals may be interrupted inside the cell by destruction of their intracellular mediators. 5 Our present data suggest that such survival signals may be suppressed at the level of their receptors, the integrins, as well as through altering the integrin ECM ligands (Figure 6 ). In a positive regulatory manner, this auxiliary apoptotic pathway would inevitably lead to further impairment of integrinmediated survival signaling. Our studies demonstrate that removal of soluble GFs from endothelial cells results in a series of molecular events that interrupt critical ECM-integrin survival signaling and thus further accelerate the apoptotic process.
Materials and Methods

Antibodies and reagents
Antibodies were generously provided as indicated or purchased. 
Cell culture and induction of apoptosis
HUVECs were cultured in RPMI 1640 supplemented with 15% calf serum (Gibco/BRL), 3% endothelial cell growth supplement, 48 and 50 mg/ml heparin (Sigma, St. Louis, MO, USA). 5, 7 Apoptosis was induced in confluent cell monolayers by incubating the cells in RPMI without GF supplementation. 5, 7 Bcl-2-overexpressing HUVECs were characterized previously. 19 Western blotting, immunoprecipitations, and zymography Cells were lysed in 50 mmol Tris/HCl, pH 7.4, 250 mmol NaCl, 0.5% NP-40, 10% glycerol, 5 mmol EDTA, 50 mmol NaF, 0.5 mmol Na 3 VO 4 , 10 mmol b-glycerophosphate, 50 mg/ml PMSF, 1 mg/ml leupeptin and aprotinin. Zymography was performed after electrophoresis in 10% polyacrylamide gels containing either casein or gelatin at 1 mg/ml. 49, 50 The gels were washed for 30 min after electrophoresis with 2.5% Triton x-100 and then incubated with 50 mM Tris, 10 mM CaCl 2 , pH 7.8, for 18 h at 378C and stained with Coomassie blue R. Incubations were performed in the presence and absence of 15 mM EDTA to confirm metalloproteinase activity. For Western blot analysis, cell proteins were separated on 10% SDS ± PAGE, and proteins were transferred to Immobilon membranes (Millipore, Bedford, MA, USA) and immunoblotted with specific antibodies. All immunoblots were visualized by chemiluminescence (Amersham Life Science Products, Arlington Heights, IL, USA). For detection of MMP2 association with integrins, either b1 or av integrins were immunoprecipitated from 250 mg cell lysate with 1 ml anti-b1 antibody or 4 ml of an anti-av antibody (MAB1978). Experiments shown were repeated at least two times unless otherwise noted.
Immunostaining to localize MT1 ± MMP, MMP2, and focal adhesions
HUVECs were plated on gelatin-coated chamber slides, grown for 48 h at 378C in media with GFs. Media were changed to that without GFs for the indicated times. At the end of the incubation, cells were fixed in 4% paraformaldehyde for 20 min at room temperature, washed two times with PBS, and permeabilized in 0.05% NP40 in PBS for 10 min. After two additional washes with PBS, quenching was performed with three 5-min incubations with 50 mM NH 4 acetate. Fixed cells were incubated with monoclonal antibodies to MMP2 (Oncogene Research Products) or MT1 ± MMP (Chemicon) or with polyclonal anti-phospho-paxillin (BioSource International) in 0.1% BSA/PBS for 1 h at room temperature followed by incubation with fluorescein-isothiocyanate-labeled anti-mouse IgG antibody (Cappel, Durham, NC, USA) or rhodamin-labeled anti-rabbit IgG (Cappel). Immunostaining was analyzed by confocal microscopy.
FACS
1 analysis of integrin levels and DNA fragmentation Cells fixed in 2% neutral buffered paraformaldehyde were incubated overnight at 48C with integrin antibodies for FACS 1 analysis with the use of a FACScan flow cytometer (BD Biosciences, San Diego, CA, USA). For analysis of DNA fragmentation, cells were fixed with icecold 70% ethanol and incubated in 1 ml of PI staining solution (50 mg/ ml PI, 0.1 mg/ml RNAse A in 0.1% NP40 and 0.1% trisodium citrate) for 20 min at 48C. Flow cytometric DNA measurements were performed on a Coulter Epics Elite (Coulter, Krefeld, Germany). Propidium iodide fluorescence was detected at 625 mm with an argon ion laser (488 mm) for exication and displayed in a peak/area versus area dot plot, with both axis and linear. After discrimination of doublets, fluorescence data were displayed in a 1.024-channel histogram by the use of a linear 4-decade scale. The portion of apoptotic cells was determined by ModFit LT Software (Verity Software House, Topsham, ME, USA).
